U.S. markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
60.13-0.63 (-1.04%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close60.76
Open60.83
Bid60.13 x 3100
Ask60.18 x 1100
Day's Range60.07 - 61.22
52 Week Range45.76 - 68.34
Volume7,336,812
Avg. Volume9,949,860
Market Cap135.529B
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.28
Earnings DateNov 05, 2020
Forward Dividend & Yield1.80 (2.99%)
Ex-Dividend DateOct 01, 2020
1y Target Est73.69
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 2 Top Pharma Stocks to Buy Right Now
    Motley Fool

    2 Top Pharma Stocks to Buy Right Now

    This alone makes it worthwhile for long-term investors to consider pharma stocks. Two that I think are worth buying right now are Bristol Myers Squibb (NYSE: BMY) and Alexion Pharmaceuticals (NASDAQ: ALXN). Both drugmakers are trading at attractive valuations: Bristol Myers' forward price-to-earnings (P/E) ratio is 8, while its price-to-earnings growth (PEG) is 0.81.

  • Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
    Zacks

    Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

  • Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy?
    Investor's Business Daily

    Bristol Myers Announced Another Major Acquisition — But Is BMY Stock A Buy?

    Bristol Myers stock has slipped this year. But acquiring Celgene has bolstered the pharmaceutical company's sales, and the pending acquisition of MyoKardia might also. So is BMY stock a buy?